Company profile
A Breakthrough in Nanosynthetic Bone Grafting
A COMBINATION EFFECT OF ENGINEERED NANOTECHNOLOGY WITH SILICATE CHEMISTRY INSTRUCTS BONE FORMATION IN BOTH VASCULAR AND AVASCULAR ENVIRONMENTS...
Updated 06 Jun 2026 16:52
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
CS01 | Transaction MzQ0MzQ1NTA4NmFkaXF6a2N4
Published 14 Nov 2024 05:03
Company registered at Companies House
1 Jun 2020 to 30 Nov 2020
no public description
1 Jan 2020 to 31 Dec 2020
SIRAKOSS developed and manufacture a novel calcium phosphate-based bone graft substitute for use in spinal and trauma surgery and the first product was recently CE-marked. This material has shown excellent performance in pre-clinical models of these surgeries but the nature of this material has a disadvantage in that it cannot be processed using high temp...
1 Sep 2017 to 30 Nov 2019
The major outcome of this project will be the development by SIRAKOSS Ltd of a bone graft substitute product that will replace the need for surgeons to harvest bone from a patient to act as a graft to repair diseased or damaged bone. Currently surgeons who are repairing fractured bones after traumatic injury, or filling a bone defect after removal of dise...
1 Jan 2015 to 31 Dec 2017
SIRAKOSS Ltd have developed a novel bone graft substitute (BGS) that will revolutionise the treatment of bone defects and fusions. Developed to offer the surgeon an alternative to having to graft the patient’s own bone, which involves a second surgical procedure associated with graft site pain and increased healthcare costs, the SIRAKOSS synthetic implant...
